Who Paid My Doc
Ashraf Mostafa
Internal Medicine Towson, MD Medical Doctor
NPI 1033279625 CMS profile 1218362
7505 Osler Drive, Suite 208, Towson, MD 21204
General payments
$145
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Ashraf Mostafa of Towson, MD is reported in the CMS Open Payments database as having received $145 across 8 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 36th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $28 | 1 | |
| 2022 | General | $43 | 3 | |
| 2020 | General | $25 | 1 | |
| 2019 | General | $50 | 3 |
Beside peers
- Ashraf Mostafa
- Internal Medicine median
- Middle half of Internal Medicine
- National median
In program year 2025, general payments to Ashraf Mostafa were reported at $28. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.
Show as a table
| Year | Ashraf Mostafa | Internal Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $50 | $159 | $48–$570 | $163 |
| 2020 | $25 | $119 | $33–$402 | $114 |
| 2021 | $0 | $135 | $37–$521 | $132 |
| 2022 | $43 | $141 | $42–$496 | $149 |
| 2023 | $0 | $149 | $45–$519 | $160 |
| 2024 | $0 | $154 | $47–$537 | $164 |
| 2025 | $28 | $156 | $47–$551 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 145 drugsPart D claims
7,216
Drug cost
$443,219
Branded share of claims
26.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 371 | $140,073 | |
| Trulicity Dulaglutide | Brand | 54 | $36,703 | |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | Brand | 122 | $20,954 | |
| Combivent Respimat Ipratropium/Albuterol Sulfate | Brand | 27 | $17,188 | |
| Jardiance Empagliflozin | Brand | 45 | $14,984 | |
| Ertapenem Ertapenem Sodium | Brand | 46 | $14,035 | |
| Protonix Pantoprazole Sodium | Brand | 65 | $13,271 | |
| Januvia Sitagliptin Phosphate | Brand | 22 | $12,461 | |
| Tradjenta Linagliptin | Brand | 35 | $9,242 | |
| Nuedexta Dextromethorphan Hbr/Quinidine | Brand | 12 | $8,769 |
The 10 drugs with the highest cost, of 145 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 12 billing codesPaid by Medicare
$479,034
Medicare patients
296
Services billed
5,334
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 59% | |
| Diabetes | 48% | |
| Ischemic heart disease | 44% | |
| Chronic kidney disease | 40% | |
| Depression | 38% | |
| Heart failure | 32% | |
| Atrial fibrillation | 28% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
8 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Internal Medicine in Maryland
Related records
Internal Medicine in Maryland
Practitioners in the same specialty and state, ranked by reported value.
All Internal Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Maryland
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.